Mike Warmuth joined EW Healthcare as an Operating Partner in May 2018 and served on the Board of Directors for Cognate Bioservices, before it was acquired by Charles River Laboratories in March 2021. Mr. Warmuth has spent his entire career with Abbott Laboratories, having joined on the manufacturing development program immediately after university.
Most recently, he spent five years as Executive Vice President, leading the Established Pharmaceuticals division, which is a leader in the sale of branded generics in emerging markets. The Established Pharmaceuticals division of Abbott is in the top ten largest generics companies globally, with revenues of >$4 billion. Mr. Warmuth held full P&L responsibility for this division, which covers several therapeutic areas including gastroenterology, women’s health, cardiovascular and metabolic disorders, pain and CNS, and respiratory drugs and vaccines. During his tenure, he led multiple M&A transactions at Abbott, including the acquisition of Chile-based CFR Pharmaceuticals for $2.9 billion in May 2014, followed by Russian pharmaceutical company, Veropharm, for $631 million in June 2014, as well as Piramal Healthcare’s prescription business for $3.7 billion in 2010, which added 350 drugs to Abbott’s portfolio.
Prior to Established Pharmaceuticals he spent almost three years as the Senior Vice President of Diagnostics, running Abbott’s global core laboratory diagnostics business. Prior thereto, Mr. Warmuth spent a brief period as GM for the Hematology division within the Diagnostics business unit. Before this, he was Vice President of the Global Engineering Services business. From 2004 to 2006, he was Division VP, Operations for the Quality and Global Pharmaceutical Operations team.
Mr. Warmuth received his Bachelors degree in Business Administration from the University of Wisconsin-Whitewater and his Masters degree in Business Administration from Northwestern University.